CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

Axia Best Managed Company Award goes to CHEPLAPHARM

Düsseldorf/Greifswald (DE), May 10, 2019 – CHEPLAPHARM Arzneimittel GmbH received the "Axia Best Managed Companies Award" (Axia BMC Award) yesterday. With the award and seal of quality, the audit and consulting firm Deloitte, WirtschaftsWoche and BDI are honouring best managed medium-sized companies.

We are absolutely delighted about this award," summarized CHEPLAPHARM’s CEO Sebastian F. Braun at the award ceremony, "because now we are ranked amongst companies and award winners as Sixt, Alfred Kärcher, Sennheiser, Vorwerk, UVEX or Hansgrohe, just to name a few. Furthermore, what we are proud of and what is now recognized is that in the last five years we achieved to become one of the top 5 medium-sized non-listed German pharmaceutical companies.

The Axia Best Managed Companies (BMC) program is a competition conducted by Deloitte, WirtschaftsWoche and BDI in Germany for successful medium-sized companies with the vision of building a national and global ecosystem of excellently managed mid-sized companies. One of BMC's unique characteristic is its international orientation: Launched by Deloitte in Canada in the 1990s, BMC is now present in thirteen countries and will be successfully launched in 2020 in at least twenty countries.

The winners of the Axia BMC Award were identified in a multi-stage, complex procedure. In the first step, companies had to complete an online questionnaire. Basic company data were queried and the positioning in the four core content areas of the award was examined: Strategy, Productivity & Innovation, Culture & Commitment, Governance & Finance. On the basis of the application documents, evaluations and personal interviews, the expert council of the Axia Best Managed Companies Award defined the shortlist. Subsequently, the winners were selected by a jury consisting of renowned representatives from business, science and media. Speaker of the jury is Dr. med. Hans-Toni Junius, Managing Partner and Chairman of the Management of C.D. Wälzholz GmbH & Co. KG and Presidential Member of the BDI.

With the Axia Best Managed Companies Award we aim to build an ecosystem and network for excellently managed mid-sized businesses - in Germany and around the world. We congratulate and look forward to welcoming CHEPLAPHARM into this exclusive circle of successful companies", added Markus Seiz, Axia BMC Program Manager.

Press Office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com


Investor Relations topics

Back to top expand_less